Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruediger E Port

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Pediatric Nephrology (Berlin, Germany)|August 13, 2008
Erythropoietin dosing in children with chronic kidney disease: based on body size or on hemoglobin deficit?Ruediger E Port, Otto Mehls
Investigational New Drugs|August 2, 2003
Noninvasive methods to study drug distributionRuediger E Port, Walter Wolf
Cancer Chemotherapy and Pharmacology|March 1, 2006
Simultaneous sustained release of fludarabine monophosphate and Gd-DTPA from an interstitial liposome depot in rats: potential for indirect monitoring of drug release by magnetic resonance imagingRuediger E Port, Christian Schuster, Christa R Port, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2012
18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake valueThomas Bengtsson, Rodney J Hicks, Amy Peterson, et al.
EJNMMI Research|February 3, 2012
Quantitation of glucose uptake in tumors by dynamic FDG-PET has less glucose bias and lower variability when adjusted for partial saturation of glucose transportSimon-Peter Williams, Judith E Flores-Mercado, Ruediger E Port, et al.
Clinical Pharmacokinetics|January 13, 2004
Recombinant human erythropoietin for the treatment of renal anaemia in children: no justification for bodyweight-adjusted dosageRuediger E Port, Daniela Kiepe, Michael Van Guilder, et al.
EJNMMI Research|June 29, 2012
The power of FDG-PET to detect treatment effects is increased by glucose correction using a Michaelis constantSimon-Peter Williams, Judith E Flores-Mercado, Andreas R Baudy, et al.
Magnetic Resonance in Medicine|May 1, 2010
An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumabGregory Z Ferl, Lu Xu, Michel Friesenhahn, et al.
Magnetic Resonance in Medicine|July 29, 2010
Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumabRuediger E Port, Lisa J Bernstein, Daniel P Barboriak, et al.
Journal of Pharmacokinetics and Pharmacodynamics|April 21, 2026
Tracer kinetic modeling of a 14 kDa anti-CD8 PET tracer (2C8v144) for in vivo estimation of CD8 expression in tissue and blood, binding affinity, and total body receptor occupancyRuediger E Port, C Andrew Boswell, Annie Ogasawara, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Pediatric Nephrology (Berlin, Germany)|August 13, 2008
Erythropoietin dosing in children with chronic kidney disease: based on body size or on hemoglobin deficit?Ruediger E Port, Otto Mehls
Investigational New Drugs|August 2, 2003
Noninvasive methods to study drug distributionRuediger E Port, Walter Wolf
Cancer Chemotherapy and Pharmacology|March 1, 2006
Simultaneous sustained release of fludarabine monophosphate and Gd-DTPA from an interstitial liposome depot in rats: potential for indirect monitoring of drug release by magnetic resonance imagingRuediger E Port, Christian Schuster, Christa R Port, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 15, 2012
18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake valueThomas Bengtsson, Rodney J Hicks, Amy Peterson, et al.
EJNMMI Research|February 3, 2012
Quantitation of glucose uptake in tumors by dynamic FDG-PET has less glucose bias and lower variability when adjusted for partial saturation of glucose transportSimon-Peter Williams, Judith E Flores-Mercado, Ruediger E Port, et al.
Clinical Pharmacokinetics|January 13, 2004
Recombinant human erythropoietin for the treatment of renal anaemia in children: no justification for bodyweight-adjusted dosageRuediger E Port, Daniela Kiepe, Michael Van Guilder, et al.
EJNMMI Research|June 29, 2012
The power of FDG-PET to detect treatment effects is increased by glucose correction using a Michaelis constantSimon-Peter Williams, Judith E Flores-Mercado, Andreas R Baudy, et al.
Magnetic Resonance in Medicine|May 1, 2010
An automated method for nonparametric kinetic analysis of clinical DCE-MRI data: application to glioblastoma treated with bevacizumabGregory Z Ferl, Lu Xu, Michel Friesenhahn, et al.
Magnetic Resonance in Medicine|July 29, 2010
Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumabRuediger E Port, Lisa J Bernstein, Daniel P Barboriak, et al.
Journal of Pharmacokinetics and Pharmacodynamics|April 21, 2026
Tracer kinetic modeling of a 14 kDa anti-CD8 PET tracer (2C8v144) for in vivo estimation of CD8 expression in tissue and blood, binding affinity, and total body receptor occupancyRuediger E Port, C Andrew Boswell, Annie Ogasawara, et al.
Pageof 2